Edgewise Therapeutics Company Insiders
| EWTX Stock | USD 26.26 0.46 1.72% |
Edgewise Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Edgewise Therapeutics suggests that vertually all insiders are panicking. Edgewise Therapeutics employs about 108 people. The company is managed by 9 executives with a total tenure of roughly 252 years, averaging almost 28.0 years of service per executive, having 12.0 employees per reported executive.
Edgewise Therapeutics' Insider Buying Vs Selling
0
Selling | Buying |
Latest Trades
| 2024-12-30 | Alan J Russell | Disposed 100000 @ 27.37 | View | ||
| 2024-12-24 | Marc Semigran | Disposed 29709 @ 29.69 | View | ||
| 2024-09-23 | John R Moore | Disposed 20922 @ 27.63 | View | ||
| 2024-09-20 | R Michael Carruthers | Disposed 125092 @ 28.57 | View | ||
| 2024-05-02 | John R Moore | Disposed 1956 @ 18.91 | View | ||
| 2024-02-09 | John R. Moore | Disposed 8029 @ 20.01 | View | ||
| 2024-02-08 | Behrad Derakhshan | Disposed 4600 @ 20.01 | View | ||
| 2024-02-07 | John R. Moore | Disposed 17993 @ 20 | View | ||
| 2024-01-23 | R Michael Carruthers | Disposed 90000 @ 15.78 | View |
Monitoring Edgewise Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Edgewise |
Edgewise Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.2236) % which means that it has lost $0.2236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.319) %, meaning that it created substantial loss on money invested by shareholders. Edgewise Therapeutics' management efficiency ratios could be used to measure how well Edgewise Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.28 in 2025. Return On Capital Employed is likely to drop to -0.33 in 2025. Net Tangible Assets is likely to rise to about 418.7 M in 2025, whereas Total Assets are likely to drop slightly above 252.6 M in 2025.Common Stock Shares Outstanding is likely to drop to about 58.4 M in 2025. Net Loss is likely to rise to about (57.8 M) in 2025
Edgewise Therapeutics Workforce Comparison
Edgewise Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,981. Edgewise Therapeutics holds roughly 108 in number of employees claiming about 5% of equities under Health Care industry.
Edgewise Therapeutics Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Edgewise Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Edgewise Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Edgewise Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
| Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
|---|---|---|---|---|---|
| 2024-12-01 | 0.5 | 3 | 6 | 199,709 | 329,418 |
| 2024-09-01 | 1.3333 | 20 | 15 | 1,758,433 | 604,302 |
| 2024-06-01 | 1.0833 | 13 | 12 | 199,541 | 55,907 |
| 2024-03-01 | 0.6429 | 9 | 14 | 1,038,925 | 259,670 |
| 2023-12-01 | 0.5 | 1 | 2 | 10,857 | 181,082 |
| 2023-06-01 | 0.9231 | 12 | 13 | 162,279 | 64,703 |
| 2022-12-01 | 1.0 | 2 | 2 | 304,730 | 9,460 |
| 2022-09-01 | 1.5 | 9 | 6 | 3,063,488 | 30,047 |
| 2022-06-01 | 2.0 | 18 | 9 | 882,821 | 125,317 |
| 2022-03-01 | 0.5 | 1 | 2 | 5,400 | 3,478,943 |
| 2021-12-01 | 0.0968 | 3 | 31 | 177,985 | 357,085 |
| 2021-09-01 | 0.75 | 6 | 8 | 1,060,000 | 85,000 |
| 2021-03-01 | 0.34 | 17 | 50 | 40,415,594 | 45,329,179 |
Edgewise Therapeutics Notable Stakeholders
An Edgewise Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Edgewise Therapeutics often face trade-offs trying to please all of them. Edgewise Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Edgewise Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Kevin Koch | CEO President | Profile | |
| MD FACP | CoFounder Chairman | Profile | |
| Badreddin Edris | CoFounder Director | Profile | |
| John Moore | General Counsel | Profile | |
| Behrad Derakhshan | Chief Officer | Profile | |
| Marc MD | Chief Officer | Profile | |
| John JD | General Counsel | Profile | |
| Alan Russell | Chief CoFounder | Profile | |
| Michael Carruthers | Chief Officer | Profile |
About Edgewise Therapeutics Management Performance
The success or failure of an entity such as Edgewise Therapeutics often depends on how effective the management is. Edgewise Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Edgewise management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Edgewise management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.32) | (0.33) | |
| Return On Assets | (0.27) | (0.28) | |
| Return On Equity | (0.36) | (0.34) |
Please note, the imprecision that can be found in Edgewise Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Edgewise Therapeutics. Check Edgewise Therapeutics' Beneish M Score to see the likelihood of Edgewise Therapeutics' management manipulating its earnings.
Edgewise Therapeutics Workforce Analysis
Traditionally, organizations such as Edgewise Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Edgewise Therapeutics within its industry.Edgewise Therapeutics Manpower Efficiency
Return on Edgewise Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 927.4K | |
| Net Loss Per Executive | 11.1M | |
| Working Capital Per Employee | 2.9M | |
| Working Capital Per Executive | 34.5M |
Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.